Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Big who wrote (51751)	12/28/1999 9:54:00 AM
From: swisstrader	Read Replies (1) \| Respond to of 108040

ARBA - thar she blows!!

To: Mr. Big who wrote (51751)	12/28/1999 9:54:00 AM
From: $Mogul	Read Replies (1) \| Respond to of 108040

Lockup on ISLD be carefull

To: Mr. Big who wrote (51751)	12/28/1999 9:58:00 AM
From: Mr Metals	Read Replies (1) \| Respond to of 108040

From the LION.COM Smaller B2B stocks are benefiting from the strengths of CMRC and ARBA. Stocks such as ELCO, BRNC, and ARIS have achieved significant market visibilities and stock price appreciations. Three undervalued stocks we like now are CNQR at $24, ASPC at $3 1/2, and WKGP at $1 3/8 which are trading at significant discounts comparing to CMRC. Our recent pick ELCO at $5 now trades above $20 in just a few short weeks. Competing with Internet stocks for investment capital is the emergent biotech sector. At this time market speculation (i.e. Linux, B2B, wireless) remains in tact, although somewhat muted. Mometum should continue in the biotech sector for the remainder of the week and undervalued plays may be traded on a momentum basis. Trade cautiously in these issues but be alert to potential opportunities. Small-cap volume is on the rise, examples; Biosource (BIOI), Ariad Pharmaceuticals (ARIA), Aastrom Biosciences (ASTM), and Incara Pharmaceuticals (INCR). ____________________________________________________________ Copyright and Disclaimer Notice The commentary is not to be reproduced, republished, broadcast or otherwise distributed without prior written permission of TheLion.com Inc. TheLion.com website and its own editorial contents are for your own personal "edutainment" use only. The editorial writing provides general stock market insights and is not solicitations of any action based upon it. The reports and stock recommendations are not to be construed as a solicitation of an offer to buy or sell any security. TheLion.com, its officers, directors, partners, employees, and anyone included in the preparation or issuance of this material may, from time to time, have a long or short position in, and buy or sell, the securities or derivatives thereof, of companies mentioned herein. It is recommended that anyone trading securities should do so with caution and consult with a broker before doing so. ____________________________________________________________ For comments please send an email to feedback@thelion.com.